2019 Q4 Form 10-Q Financial Statement

#000106282219000028 Filed on November 07, 2019

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q3 2018 Q4
Revenue $8.727M $294.4M $17.07M
YoY Change -48.88% 4126.93% -49.74%
Cost Of Revenue $800.0K $577.0K $600.0K
YoY Change 33.33% 4.72% 20.0%
Gross Profit $8.000M $293.9M $16.80M
YoY Change -52.38% 4481.0% -50.44%
Gross Profit Margin 91.67% 99.8% 98.41%
Selling, General & Admin $14.60M $13.90M $16.60M
YoY Change -12.05% -10.9% 3.75%
% of Gross Profit 182.5% 4.73% 98.81%
Research & Development $40.60M $26.66M $12.10M
YoY Change 235.54% 93.7% -71.6%
% of Gross Profit 507.5% 9.07% 72.02%
Depreciation & Amortization $1.000M $900.0K $900.0K
YoY Change 11.11% 0.0% 0.0%
% of Gross Profit 12.5% 0.31% 5.36%
Operating Expenses $55.10M $69.77M $28.60M
YoY Change 92.66% 133.41% -51.19%
Operating Profit -$47.22M $224.7M -$12.37M
YoY Change 281.8% -1079.96% -57.38%
Interest Expense -$5.200M $5.204M -$5.200M
YoY Change 0.0% -0.91% 136.36%
% of Operating Profit 2.32%
Other Income/Expense, Net $1.300M $600.0K $800.0K
YoY Change 62.5% -23.37% 33.33%
Pretax Income -$51.10M $220.1M -$16.30M
YoY Change 213.5% -903.3% -38.02%
Income Tax $0.00 -$6.000M $0.00
% Of Pretax Income -2.73%
Net Earnings -$51.14M $226.1M -$16.78M
YoY Change 204.72% -925.25% -36.93%
Net Earnings / Revenue -585.97% 76.78% -98.31%
Basic Earnings Per Share -$0.48 $2.13
Diluted Earnings Per Share -$0.48 $1.95 -$153.9K
COMMON SHARES
Basic Shares Outstanding 106.3M shares 106.3M shares 105.9M shares
Diluted Shares Outstanding 106.3M shares 116.6M shares

Balance Sheet

Concept 2019 Q4 2019 Q3 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $271.7M $296.3M $160.1M
YoY Change 69.71% 58.2% -48.49%
Cash & Equivalents $36.11M $170.2M $80.39M
Short-Term Investments $235.5M $126.1M $79.70M
Other Short-Term Assets $5.320M $5.973M $2.668M
YoY Change 99.4% 75.94% -39.83%
Inventory $4.243M $4.476M $4.680M
Prepaid Expenses
Receivables $56.53M $56.84M $5.924M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $337.8M $363.6M $173.3M
YoY Change 94.87% 83.3% -46.17%
LONG-TERM ASSETS
Property, Plant & Equipment $14.05M $14.54M $15.87M
YoY Change -11.46% -10.79% -10.3%
Goodwill $44.54M $44.54M $44.54M
YoY Change 0.0% 0.0% 0.0%
Intangibles $19.70M $20.16M $50.12M
YoY Change -60.69% -60.13% -3.4%
Long-Term Investments
YoY Change
Other Assets $1.655M $1.754M $285.0K
YoY Change 480.7% 308.86% -33.57%
Total Long-Term Assets $79.96M $80.99M $110.8M
YoY Change -27.84% -27.58% -3.26%
TOTAL ASSETS
Total Short-Term Assets $337.8M $363.6M $173.3M
Total Long-Term Assets $79.96M $80.99M $110.8M
Total Assets $417.7M $444.6M $284.1M
YoY Change 47.01% 43.33% -34.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.18M $20.91M $12.05M
YoY Change 1.05% -59.39% -68.91%
Accrued Expenses $42.15M $11.51M $21.25M
YoY Change 98.4% -16.55% 72.98%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $11.01M $11.29M $1.115M
YoY Change 887.62% 912.47% -92.09%
Total Short-Term Liabilities $65.34M $44.82M $36.75M
YoY Change 77.79% -34.57% -65.16%
LONG-TERM LIABILITIES
Long-Term Debt $234.2M $233.8M $243.9M
YoY Change -3.98% -4.1% 5.32%
Other Long-Term Liabilities $1.102M $1.215M $238.0K
YoY Change 363.03% 382.14% -18.49%
Total Long-Term Liabilities $235.3M $235.1M $244.1M
YoY Change -3.63% -3.7% 5.29%
TOTAL LIABILITIES
Total Short-Term Liabilities $65.34M $44.82M $36.75M
Total Long-Term Liabilities $235.3M $235.1M $244.1M
Total Liabilities $300.6M $279.9M $310.5M
YoY Change -3.2% -17.58% -15.68%
SHAREHOLDERS EQUITY
Retained Earnings -$1.341B -$1.290B -$1.472B
YoY Change -8.84% -12.31% 7.79%
Common Stock $106.0K $106.0K $106.0K
YoY Change 0.0% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost) $3.817M $3.817M $2.876M
YoY Change 32.72% 32.72% 51.05%
Treasury Stock Shares 407.0K shares 407.0K shares 236.0K shares
Shareholders Equity $117.1M $164.7M -$26.41M
YoY Change
Total Liabilities & Shareholders Equity $417.7M $444.6M $284.1M
YoY Change 47.01% 43.33% -34.91%

Cashflow Statement

Concept 2019 Q4 2019 Q3 2018 Q4
OPERATING ACTIVITIES
Net Income -$51.14M $226.1M -$16.78M
YoY Change 204.72% -925.25% -36.93%
Depreciation, Depletion And Amortization $1.000M $900.0K $900.0K
YoY Change 11.11% 0.0% 0.0%
Cash From Operating Activities -$24.40M $190.7M -$27.10M
YoY Change -9.96% -959.01% -19.58%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$109.4M -$31.30M $58.80M
YoY Change -286.05% -155.5% -143.33%
Cash From Investing Activities -$109.4M -$31.30M $58.80M
YoY Change -286.05% -155.5% -143.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -300.0K -300.0K -100.0K
YoY Change 200.0% -25.0% -100.07%
NET CHANGE
Cash From Operating Activities -24.40M 190.7M -27.10M
Cash From Investing Activities -109.4M -31.30M 58.80M
Cash From Financing Activities -300.0K -300.0K -100.0K
Net Change In Cash -134.1M 159.1M 31.60M
YoY Change -524.37% 370.71% -245.62%
FREE CASH FLOW
Cash From Operating Activities -$24.40M $190.7M -$27.10M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$24.40M $190.7M -$27.10M
YoY Change -9.96% -959.01% -19.58%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Document Period End Date
DocumentPeriodEndDate
2019-09-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001062822
CY2019Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
106271927 shares
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2019Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Registrant Name
EntityRegistrantName
LEXICON PHARMACEUTICALS, INC./DE
CY2019Q3 dei Entity Shell Company
EntityShellCompany
false
dei Entity Small Business
EntitySmallBusiness
false
CY2019Q3 lxrx Buildings Collateral
BuildingsCollateral
59200000 USD
CY2014Q4 lxrx Conv Debt Instrument Interest Rate Stated Percentage
ConvDebtInstrumentInterestRateStatedPercentage
0.0525
lxrx Ipsen Maximum Regulatory And Commercial Milestones
IpsenMaximumRegulatoryAndCommercialMilestones
9600000 USD
CY2014Q4 lxrx Ipsen Maximum Sales Milestones
IpsenMaximumSalesMilestones
72000000 EUR
CY2016Q3 lxrx Ipsen Milestone Payment
IpsenMilestonePayment
6400000 USD
lxrx Ipsen Milestone Payment
IpsenMilestonePayment
6400000 USD
lxrx Ipsen Milestone Payment
IpsenMilestonePayment
5100000 USD
CY2017Q4 lxrx Ipsen Milestone Payment Received
IpsenMilestonePaymentReceived
3840000 USD
CY2017Q4 lxrx Ipsen Milestone Payment Received
IpsenMilestonePaymentReceived
3840000 USD
CY2019Q1 lxrx Ipsen Milestone Payment Received
IpsenMilestonePaymentReceived
2250000 USD
CY2018Q3 lxrx Ipsen Milestone Payment Received
IpsenMilestonePaymentReceived
5100000 USD
CY2018Q4 lxrx Ipsen Milestone Payment Received
IpsenMilestonePaymentReceived
1250000 USD
lxrx Ipsen Product Revenue
IpsenProductRevenue
1400000 USD
lxrx Ipsen Product Revenue
IpsenProductRevenue
1300000 USD
CY2014Q4 lxrx Ipsen Revenue Allocatedto Committee Deliverable
IpsenRevenueAllocatedtoCommitteeDeliverable
100000 USD
CY2019Q3 lxrx Lxrx Sanofiterminationcashpayment
Lxrx_Sanofiterminationcashpayment
208000000 USD
CY2019Q3 lxrx Lxrx Deferredrevenuebalance
Lxrx_deferredrevenuebalance
23500000 USD
CY2019Q3 lxrx Lxrx Sanofifuturecashpayment
Lxrx_sanofifuturecashpayment
52000000 USD
CY2018Q3 lxrx Mortgage Debt Balloon Payment Lxrx
MortgageDebtBalloonPayment_LXRX
10300000 USD
CY2019Q3 lxrx Mortgage Debt Instrument Revere Lxrx
MortgageDebtInstrument_Revere_LXRX
11300000 USD
CY2018Q3 lxrx Mortgage Debt Instrument Revere Lxrx
MortgageDebtInstrument_Revere_LXRX
12900000 USD
CY2018Q3 lxrx Mortgage Debt Interest Rate Base Plus Revere Lxrx
MortgageDebtInterestRateBasePlus_Revere_LXRX
0.075
CY2018Q3 lxrx Mortgage Debt Interest Rate Base Revere Lxrx
MortgageDebtInterestRate_Base_Revere_LXRX
0.055
CY2019Q3 lxrx Mortgage Debt Issue Costs Revere Lxrx
MortgageDebtIssueCosts_Revere_LXRX
200000 USD
CY2018Q3 lxrx Mortgage Debt Issue Costs Revere Lxrx
MortgageDebtIssueCosts_Revere_LXRX
400000 USD
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2018Q3 lxrx Netproductrevenue
Netproductrevenue
6286000 USD
lxrx Netproductrevenue
Netproductrevenue
19062000 USD
CY2019Q3 lxrx Netproductrevenue
Netproductrevenue
8351000 USD
lxrx Netproductrevenue
Netproductrevenue
23763000 USD
CY2014Q4 lxrx Ipsen Revenue Allocatedto Development Deliverable
IpsenRevenueAllocatedtoDevelopmentDeliverable
1700000 USD
CY2014 lxrx Ipsen Revenue Allocatedto License Deliverable
IpsenRevenueAllocatedtoLicenseDeliverable
21200000 USD
CY2015 lxrx Ipsen Revenue Allocatedto License Deliverable
IpsenRevenueAllocatedtoLicenseDeliverable
1400000 USD
lxrx Ipsen Revenue Recognized
IpsenRevenueRecognized
1100000 USD
lxrx Ipsen Revenue Recognized
IpsenRevenueRecognized
3500000 USD
lxrx Ipsen Royalty Income Lxrx
IpsenRoyaltyIncome_LXRX
100000 USD
lxrx Ipsen Royalty Income Lxrx
IpsenRoyaltyIncome_LXRX
200000 USD
lxrx Ipsen Royalty Income Lxrx
IpsenRoyaltyIncome_LXRX
300000 USD
CY2019Q3 lxrx Ipsen Total Payments
IpsenTotalPayments
47200000 USD
CY2015Q1 lxrx Ipsen Total Upfront Payments
IpsenTotalUpfrontPayments
24500000 USD
CY2019Q3 lxrx Land Collateral
LandCollateral
2700000 USD
CY2019Q3 lxrx Lxrx Sanofiterminationagreement
Lxrx_Sanofiterminationagreement
260000000 USD
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2015Q4 lxrx Sanofi Commercialization Costs Fundedby Lexicon Maximum Amount
SanofiCommercializationCostsFundedbyLexiconMaximumAmount
100000000 USD
CY2015Q4 lxrx Sanofi Development Milestones
SanofiDevelopmentMilestones
110000000 USD
CY2015Q4 lxrx Sanofi Outcomes Study Milestone
SanofiOutcomesStudyMilestone
100000000 USD
CY2015Q4 lxrx Sanofi Regulatory Milestones
SanofiRegulatoryMilestones
220000000 USD
CY2015Q4 lxrx Sanofi Revenue Allocatedto Development Deliverable
SanofiRevenueAllocatedtoDevelopmentDeliverable
113800000 USD
CY2015Q4 lxrx Sanofi Revenue Allocatedto Funding Deliverable
SanofiRevenueAllocatedtoFundingDeliverable
59400000 USD
CY2015Q4 lxrx Sanofi Revenue Allocatedto License Deliverable
SanofiRevenueAllocatedtoLicenseDeliverable
126800000 USD
lxrx Sanofi Revenue Recognized
SanofiRevenueRecognized
25600000 USD
lxrx Sanofi Revenue Recognized
SanofiRevenueRecognized
286000000 USD
CY2015Q4 lxrx Sanofi Sales Milestone Payments
SanofiSalesMilestonePayments
990000000 USD
CY2015Q4 lxrx Sanofi Upfront Payment
SanofiUpfrontPayment
300000000 USD
CY2018Q3 lxrx Sellinggeneralandadministrativeexpenses
Sellinggeneralandadministrativeexpenses
15579000 USD
lxrx Sellinggeneralandadministrativeexpenses
Sellinggeneralandadministrativeexpenses
47191000 USD
CY2019Q3 lxrx Sellinggeneralandadministrativeexpenses
Sellinggeneralandadministrativeexpenses
13898000 USD
lxrx Sellinggeneralandadministrativeexpenses
Sellinggeneralandadministrativeexpenses
42271000 USD
CY2018Q3 lxrx Stock Based Compensation Expense Associated With Research And Development Expense
StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
1472000 USD
lxrx Stock Based Compensation Expense Associated With Research And Development Expense
StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
4522000 USD
CY2019Q3 lxrx Stock Based Compensation Expense Associated With Research And Development Expense
StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
1698000 USD
lxrx Stock Based Compensation Expense Associated With Research And Development Expense
StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
5369000 USD
CY2018Q3 lxrx Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense
Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense
1405000 USD
lxrx Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense
Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense
4327000 USD
CY2019Q3 lxrx Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense
Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense
1864000 USD
lxrx Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense
Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense
5370000 USD
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
17759000 USD
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
20907000 USD
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5924000 USD
CY2019Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
56841000 USD
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14482000 USD
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11511000 USD
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
60006000 USD
CY2019Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
61257000 USD
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-12000 USD
CY2019Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
36000 USD
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1447954000 USD
CY2019Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1458693000 USD
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3074000 USD
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2898000 USD
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2877000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3766000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3411000 USD
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3562000 USD
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
4000 USD
CY2019Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
4000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
957000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1087000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1300000 USD
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7501000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7501000 shares
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10576000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8452000 shares
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2018Q4 us-gaap Assets
Assets
284136000 USD
CY2019Q3 us-gaap Assets
Assets
444588000 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
173324000 USD
CY2019Q3 us-gaap Assets Current
AssetsCurrent
363594000 USD
CY2018Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
79666000 USD
CY2019Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
126101000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61661000 USD
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48902000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
80386000 USD
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
170203000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
80386000 USD
CY2019Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
170203000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-12759000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
89817000 USD
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
225000000 shares
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
225000000 shares
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
106000 USD
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
106000 USD
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27249000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-103614000 USD
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
226036000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
181319000 USD
CY2018Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
551000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1922000 USD
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
577000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2457000 USD
CY2014Q4 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
8.442
CY2014Q4 us-gaap Debt Instrument Convertible Conversion Ratio1
DebtInstrumentConvertibleConversionRatio1
118.4553
CY2017Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
150000000 USD
CY2019Q3 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
76000000 USD
CY2019Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.09
CY2019Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
2600000 USD
CY2018Q3 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 USD
us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 USD
CY2019Q3 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-6014000 USD
us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-6014000 USD
CY2017Q4 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
4100000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-6014000 USD
CY2018Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3395000 USD
CY2019Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1117000 USD
CY2018Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
23651000 USD
CY2019Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0 USD
CY2018Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
6014000 USD
CY2019Q3 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
0 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2771000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2719000 USD
CY2018Q3 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
0 USD
us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
0 USD
CY2019Q3 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
1277000 USD
us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
3790000 USD
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.98
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.71
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.98
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.95
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.59
CY2018Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3237000 USD
CY2019Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4561000 USD
CY2018Q4 us-gaap Goodwill
Goodwill
44543000 USD
CY2019Q3 us-gaap Goodwill
Goodwill
44543000 USD
CY2019Q3 us-gaap Impaired Assets To Be Disposed Of By Method Other Than Sale Carrying Value Of Asset
ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset
0 USD
CY2018Q3 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0 USD
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0 USD
CY2019Q3 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
28638000 USD
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
28638000 USD
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27396000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-103765000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
220072000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
175257000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4906000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-645000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1912000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
50917000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-25529000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-25929000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2807000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-204000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-330000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1039000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3305000 USD
CY2018Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0 shares
CY2019Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
10365000 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
10365000 shares
CY2018Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2019Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
177000 shares
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
50119000 USD
CY2019Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
20157000 USD
CY2018Q4 us-gaap Inventory Gross
InventoryGross
4680000 USD
CY2018Q3 us-gaap Interest Expense
InterestExpense
5252000 USD
us-gaap Interest Expense
InterestExpense
15552000 USD
CY2019Q3 us-gaap Interest Expense
InterestExpense
5204000 USD
us-gaap Interest Expense
InterestExpense
15485000 USD
us-gaap Interest Paid Net
InterestPaidNet
10470000 USD
us-gaap Interest Paid Net
InterestPaidNet
13243000 USD
CY2018Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
884000 USD
CY2019Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1095000 USD
CY2019Q3 us-gaap Inventory Gross
InventoryGross
4476000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2049000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
0 USD
CY2018Q4 us-gaap Inventory Net
InventoryNet
4680000 USD
CY2019Q3 us-gaap Inventory Net
InventoryNet
4476000 USD
CY2018Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
3564000 USD
CY2019Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
3228000 USD
CY2018Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
232000 USD
CY2019Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
153000 USD
CY2018Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
160052000 USD
CY2019Q3 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
296304000 USD
CY2019Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.09
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
152000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
645000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
632000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
620000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
281000 USD
CY2018Q4 us-gaap Liabilities
Liabilities
310541000 USD
CY2019Q3 us-gaap Liabilities
Liabilities
279876000 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
284136000 USD
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
444588000 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
36751000 USD
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
44824000 USD
CY2018Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1115000 USD
CY2019Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
11289000 USD
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
243887000 USD
CY2019Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
233837000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2105000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1904000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
110825000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-46457000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-121479000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
138178000 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-27396000 USD
us-gaap Net Income Loss
NetIncomeLoss
-103765000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
226086000 USD
us-gaap Net Income Loss
NetIncomeLoss
181271000 USD
CY2018Q1 us-gaap New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption Quantification
NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification
14212000 USD
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
29893000 USD
us-gaap Operating Expenses
OperatingExpenses
137049000 USD
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
69772000 USD
us-gaap Operating Expenses
OperatingExpenses
124684000 USD
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-22927000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-90911000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
224676000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
188662000 USD
CY2019Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
553000 USD
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1768000 USD
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
53000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
45000 USD
CY2018Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-172000 USD
CY2018Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
176000 USD
CY2018Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
147000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
151000 USD
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1800000 USD
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2100000 USD
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2668000 USD
CY2019Q3 us-gaap Other Assets Current
OtherAssetsCurrent
5973000 USD
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
285000 USD
CY2019Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1754000 USD
CY2019Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
600000 USD
CY2019Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1200000 USD
CY2019Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1215000 USD
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-50000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
48000 USD
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
238000 USD
CY2019Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1215000 USD
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
783000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2698000 USD
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
600000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2080000 USD
CY2014Q4 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
3400000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
972000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
941000 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
84475000 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
176987000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
58000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
70000 USD
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2019Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q4 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
87500000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
550000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
12529000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
195358000 USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
130600000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15865000 USD
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14540000 USD
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
14212000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
963000 USD
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13763000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
87936000 USD
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26659000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
51318000 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1471577000 USD
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1290306000 USD
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
556000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26792000 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
285910000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
289209000 USD
CY2018Q3 us-gaap Revenues
Revenues
6966000 USD
us-gaap Revenues
Revenues
46138000 USD
CY2019Q3 us-gaap Revenues
Revenues
294448000 USD
us-gaap Revenues
Revenues
313346000 USD
CY2018Q3 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
124000 USD
us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
284000 USD
CY2019Q3 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
187000 USD
us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
374000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
8849000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
10739000 USD
CY2018Q4 us-gaap Short Term Investments
ShortTermInvestments
79666000 USD
CY2019Q3 us-gaap Short Term Investments
ShortTermInvestments
126101000 USD
CY2018Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25000 USD
CY2018Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
367000 USD
CY2018Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
158000 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
0 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-26405000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
164712000 USD
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
68265000 USD
CY2018Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
42612000 USD
CY2018Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
11504000 USD
CY2018Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-12710000 USD
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-26405000 USD
CY2019Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
164712000 USD
CY2018Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
236000 shares
CY2019Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
407000 shares
CY2018Q4 us-gaap Treasury Stock Value
TreasuryStockValue
2876000 USD
CY2019Q3 us-gaap Treasury Stock Value
TreasuryStockValue
3817000 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
972000 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
941000 USD
CY2019Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
1000000 USD
CY2018Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
-27396000 USD
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
-103765000 USD
CY2019Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
227363000 USD
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
185061000 USD
CY2018Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
-27396000 USD
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
-103765000 USD
CY2019Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
227363000 USD
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
185061000 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
151000 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
48000 USD
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
105881000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
105800000 shares
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
116640000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
116742000 shares
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
105881000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
105800000 shares
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
106272000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
106200000 shares
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentration of Credit Risk:</font><font style="font-family:inherit;font-size:10pt;"> Lexicon&#8217;s cash equivalents, short-term investments and accounts receivable represent potential concentrations of credit risk. The Company attempts to minimize potential concentrations of risk in cash equivalents and short-term investments by placing investments in high-quality financial instruments. The Company&#8217;s accounts receivable are unsecured and are concentrated in pharmaceutical and biotechnology companies located in Europe and the United States.&#160;&#160;The Company has not experienced any significant credit losses to date.&#160;&#160;</font></div></div>
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates:</font><font style="font-family:inherit;font-size:10pt;"> The preparation of financial statements in conformity with U. S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name View Source Status
0001062822-19-000028-index-headers.html Edgar Link pending
0001062822-19-000028-index.html Edgar Link pending
0001062822-19-000028.txt Edgar Link pending
0001062822-19-000028-xbrl.zip Edgar Link pending
exh101terminationsettlemen.htm Edgar Link pending
exh311certificationofprinc.htm Edgar Link pending
exh312certificationofprinc.htm Edgar Link pending
exh321certificationofprinc.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
lxrx-20190930.xml Edgar Link completed
lxrx-20190930.xsd Edgar Link pending
lxrx-20190930_cal.xml Edgar Link unprocessable
lxrx-20190930_def.xml Edgar Link unprocessable
lxrx-20190930_lab.xml Edgar Link unprocessable
lxrx-20190930_pre.xml Edgar Link unprocessable
lxrx930201910-q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending